GAITHERSBURG, Md., Sept 1 — GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.
“What makes this recognition so meaningful is seeing genomics take its place in the broader healthcare conversation,” said Stueland. “We know that when patients get the right diagnosis earlier, everything that follows can change. Genomic medicine has the power to fundamentally improve how care is delivered, and at GeneDx, we’re proving what’s possible when genomics becomes part of the standard of care.”
Under Stueland’s leadership, GeneDx is making earlier, more accurate diagnosis a standard part of healthcare. By combining deep clinical expertise, advanced technology and GeneDx Infinity™, the world’s largest rare disease genomic dataset, the company is bringing genomic medicine into clinical care at scale to enable a more proactive, precise and efficient healthcare system.
“Now in its fourth year, the Fierce 50 continues to show that progress in this industry doesn’t come from just one place,” said Ayla Ellison, editor-in-chief of Fierce Life Sciences and Healthcare. “It’s showing up in the lab, in executive leadership, in community clinics and in advocacy work that never makes headlines. Whether it’s a biotech pushing a new therapy toward patients or a grassroots organization fighting for someone to get the care they need, these honorees remind us that impact takes a lot of different shapes. We’re honored to celebrate all of them.”